(NewsDirect)
Theralase Technologies CEO RogerDuMoulin-White joined Steve Darling from Proactive to share interimdata from a Phase II clinical study designed to treat patientsdiagnosed with Bacillus Calmette-Guérin Unresponsive, Non-MuscleInvasive Bladder Cancer and Carcinoma In-Situ with a patentedinvestigational study drug Ruvidar, subsequently activated by aproprietary investigational study laser system equipped withfiber-optic light emitters and detectors.
DuMoulin-White discussed more about the study and what theinterim data is telling them about the study.
He also talkedabout the company and the other vertical it has with its Cool LaserTherapy which is focused on the research, development, production anddistribution of medical laser technologies for healing pain.
Contact Details
Proactive Investors
+1604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.